GERD and Refractory Reflux
The Lyon Consensus framework for proving reflux: when pH-impedance confirms it, when it doesn't, and what to do with refractory symptoms. PPI failure, vonoprazan and other PCABs, fundoplication candidacy, and the brain-gut diagnoses (NERD, reflux hypersensitivity, functional heartburn) that masquerade as treatment-resistant disease.
- Audio chapterSingle-voice audio, listen on the commute.
- ABIM-format MCQs5-option vignettes with full wrong-answer teaching.
- Study guideTables, decision trees, primary sources.
- AI tutorChapter-grounded, answers the question you're stuck on.
What this chapter covers
- Section 3.1: Antireflux barrier physiology and pathogenesis
GERD is a barrier failure problem before it is an acid problem.
- Section 3.2: Endoscopic findings and Los Angeles classification
The endoscopic pattern in a GERD vignette stratifies treatment intensity, surveillance obligations, and surgical candidacy in a single image.
- Section 3.3: Acid suppression therapy ladder and PPI safety
The acid suppression ladder is the workhorse of GERD therapy and the mechanism of every step on it is parietal cell-centric.
- Section 3.4: pH-impedance testing and the Lyon Consensus
Reflux monitoring is the test that decides whether a patient with persistent symptoms actually has GERD, has a borderline reflux burden that may or may not explain the symptoms, has reflux hypersensitivity, or has functional heartburn.
- Section 3.5: Antireflux surgery and endoscopic therapies
The operation for GERD is selected on motility status, hiatal hernia size, body mass index, and patient preference, and the surgical question is best approached as a matching problem rather than as a default referral.
- Section 3.6: Refractory GERD evaluation and management
Refractory GERD is the workup run when a patient on optimized acid suppression continues to have symptoms, and the framework is mechanism-driven.
Podcast episodes
- 01
Mechanisms and Endoscopy
GERD is a failure of the antireflux barrier, not acid overproduction. Most patients have a normal resting sphincter, so transient lower esophageal sphincter relaxations are the dominant mechanism, and a sliding hiatal hernia amplifies every failure mode at once. Endoscopy grades the erosive damage, sizes the hernia, and decides treatment intensity, surveillance, and surgical candidacy from one look.
Read the transcript → - 02
Acid Suppression Drugs
Acid-suppressing drugs work only when their mechanism and timing line up. This episode explains why proton pump inhibitors heal erosive disease when histamine blockers fade, why wrong meal timing is the top cause of apparent PPI failure, and where vonoprazan changes the game.
Read the transcript → - 03
Refractory Lyon Surgery Functional
Drug failure on twice-daily acid suppression is not refractory reflux, it is a reason to work the patient up, and the workup usually turns up something other than reflux. The Lyon Consensus framework, with its acid-exposure cutoffs and symptom-association tests, sorts persistent symptoms into confirmed reflux, borderline, reflux hypersensitivity, and functional heartburn. Antireflux surgery is matched to proven reflux and to motility, and it is reserved for the small group left standing after the mimics are excluded.
Read the transcript →
Key topics
- Barrier failure, not acid excess
- LES plus crural diaphragm stacked as one valve
- Transient LES relaxations as the main mechanism
- Sliding hiatal hernia amplifies every failure mode
- Postprandial acid pocket and the alginate raft
- Failed acid clearance: supine, saliva loss, weak swallow
- Obesity, visceral pressure, and Barrett risk
- LA-grade erosive esophagitis and its consequences
- One pump, three switches: gastrin, histamine, acetylcholine
- H2 blockers fade as the cell ramps up
- PPIs are prodrugs that need meal-timed acid
- PPI potency ranking and escalation logic
- Nocturnal acid breakthrough on twice-daily dosing
- Vonoprazan as a mechanistically different acid blocker
- Long-term safety associations versus randomized data
- Clopidogrel and PPI interaction
- PPI failure is a different diagnosis, not breakthrough reflux
- Lyon Consensus: proof, support, and evidence against
- Testing on-drug versus off-drug depends on what you must prove
- Four buckets: confirmed, borderline, hypersensitivity, functional heartburn
- Matching wrap type to esophageal motility
- Magnetic device, incisionless fundoplication, and bariatric options
- The ordered refractory workup and its mimics
- Atypical presentations and weak reflux linkage
Sources
Guidelines, consensus statements, and validated instruments this chapter draws on. Named here because the chapter applies them directly.
Professional society guidelines
- American College of Gastroenterology (ACG)
Classification and diagnostic criteria
- Chicago Classification (esophageal motility)
- Prague C&M criteria (Barrett extent)